Goldman Sachs Group Inc Citius Pharmaceuticals, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CTXR
# of Institutions
61Shares Held
23.7MCall Options Held
83.1KPut Options Held
32.1K-
Armistice Capital, LLC New York, NY7.28MShares$18.8 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.44MShares$16.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$4.87 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.81MShares$4.68 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.16MShares$3 Million0.0% of portfolio
About Citius Pharmaceuticals, Inc.
- Ticker CTXR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 146,130,000
- Market Cap $378M
- Description
- Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...